Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 5/20 | 0.47 |
| ▸ | JAK3 | P52333 | 6/20 | 0.45 |
| ▸ | JAK2 | O60674 | 6/20 | 0.45 |
| ▸ | JAK1 | P23458 | 4/20 | 0.45 |
| ▸ | TYK2 | P29597 | 2/20 | 0.45 |
| ▸ | IGF1R | P08069 | 4/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
| ▸ | CDK7 | P50613 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22097704 | 0.88 | JAK3 (0.47) | MAP4K1JAK3JAK2JAK1TYK2 | |
| SCHEMBL22544617 | 0.87 | MAP4K1 (0.49) | MAP4K1JAK3JAK2JAK1TYK2 | |
| SCHEMBL24852530 | 0.86 | IGF1R (0.46) | MAP4K1JAK3JAK2JAK1TYK2 | |
| SCHEMBL22097909 | 0.84 | LRRK2 (0.48) | MAP4K1JAK3JAK2JAK1TYK2 | |
| SCHEMBL31557682 | 0.84 | LRRK2 (0.48) | MAP4K1JAK3JAK2JAK1TYK2 | |
| SCHEMBL22097851 | 0.83 | JAK2 (0.50) | JAK3JAK2JAK1TYK2IGF1R | |
| SCHEMBL24853381 | 0.82 | IGF1R (0.44) | MAP4K1JAK3JAK2JAK1TYK2 | |
| SCHEMBL22098037 | 0.82 | IGF1R (0.44) | MAP4K1JAK3JAK2JAK1TYK2 | |
| SCHEMBL24852538 | 0.82 | JAK2 (0.49) | JAK3JAK2JAK1TYK2DDR2 | |
| SCHEMBL24853212 | 0.82 | JAK3 (0.45) | MAP4K1JAK3JAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025882-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025882-A1 | BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK2, JAK1, JAK3 | MAP4K1 148/4885JAK3 3/4885JAK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.